RT Journal Article
SR Electronic
T1 The management of dry eye
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 9
OP 12
DO 10.1136/dtb.2016.1.0378
VO 54
IS 1
YR 2016
UL http://dtb.bmj.com/content/54/1/9.abstract
AB Dry eye disease (also called keratoconjunctivitis sicca) is a common condition, with a prevalence ranging from 8–34%, depending on the criteria used.1 It becomes more common with increasing age and affects more women than men. Artificial tears and ocular lubricants are considered the mainstay of treatment and there is a very wide range of these products available. In England in 2014, over 6.4 million prescription items for artificial tears, ocular lubricants and astringents were dispensed in the community at a cost to the NHS of over £27 million.2 In this article we review the management of dry eye disease, focusing on artificial tears and ocular lubricants.